We’ve recently updated our valuation analysis.

ANGLE Valuation

Is AGL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AGL?

Other financial metrics that can be useful for relative valuation.

AGL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue110.4x
Enterprise Value/EBITDA-7.2x
PEG Ration/a

Price to Book Ratio vs Peers

How does AGL's PB Ratio compare to its peers?

The above table shows the PB ratio for AGL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average3.3x
EKF EKF Diagnostics Holdings
2.3x30.0%UK£192.9m
AVO Advanced Oncotherapy
1.5x56.7%UK£90.3m
BELL Belluscura
4.1x92.7%UK£80.6m
POLX Polarean Imaging
5.3xn/aUK£111.8m
AGL ANGLE
4.4x11.3%UK£140.6m

Price-To-Book vs Peers: AGL is expensive based on its Price-To-Book Ratio (4.4x) compared to the peer average (3.3x).


Price to Earnings Ratio vs Industry

How does AGL's PE Ratio compare vs other companies in the GB Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.8%
n/an/an/a

Price-To-Book vs Industry: AGL is expensive based on its Price-To-Book Ratio (4.4x) compared to the UK Medical Equipment industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is AGL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AGL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate AGL's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of AGL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AGL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AGL's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AGL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£0.54
UK£2.06
+280.6%
17.3%UK£2.41UK£1.70n/a2
Nov ’23UK£0.60
UK£2.06
+242.5%
17.3%UK£2.41UK£1.70n/a2
Oct ’23UK£0.67
UK£2.21
+229.1%
9.3%UK£2.41UK£2.00n/a2
Sep ’23UK£0.69
UK£2.16
+211.4%
7.2%UK£2.31UK£2.00n/a2
Aug ’23UK£0.76
UK£2.16
+183.6%
7.2%UK£2.31UK£2.00n/a2
Jul ’23UK£0.97
UK£2.16
+121.0%
7.2%UK£2.31UK£2.00n/a2
Jun ’23UK£1.39
UK£2.16
+55.0%
7.2%UK£2.31UK£2.00n/a2
May ’23UK£1.03
UK£1.85
+79.6%
4.4%UK£1.95UK£1.75n/a3
Apr ’23UK£1.07
UK£1.85
+72.9%
4.4%UK£1.95UK£1.75n/a3
Mar ’23UK£0.76
UK£1.85
+145.0%
4.4%UK£1.95UK£1.75n/a3
Feb ’23UK£1.09
UK£1.85
+69.3%
4.4%UK£1.95UK£1.75n/a3
Jan ’23UK£1.19
UK£1.75
+47.1%
0%UK£1.75UK£1.75n/a1
Dec ’22UK£1.37
UK£1.75
+28.2%
0%UK£1.75UK£1.75n/a1
Nov ’22UK£1.22
UK£1.75
+43.4%
0%UK£1.75UK£1.75UK£0.601
Oct ’22UK£1.35
UK£1.75
+29.6%
0%UK£1.75UK£1.75UK£0.671
Sep ’22UK£1.13
UK£1.75
+54.9%
0%UK£1.75UK£1.75UK£0.691
Aug ’22UK£1.09
UK£1.75
+60.2%
0%UK£1.75UK£1.75UK£0.761
Jul ’22UK£1.36
UK£1.75
+29.2%
0%UK£1.75UK£1.75UK£0.971
Jun ’22UK£1.37
UK£1.65
+20.4%
0%UK£1.65UK£1.65UK£1.391
May ’22UK£1.17
UK£1.65
+41.6%
0%UK£1.65UK£1.65UK£1.031
Apr ’22UK£0.81
UK£1.50
+84.5%
0%UK£1.50UK£1.50UK£1.071
Mar ’22UK£0.84
UK£1.50
+79.0%
0%UK£1.50UK£1.50UK£0.761
Feb ’22UK£0.78
UK£1.50
+92.3%
0%UK£1.50UK£1.50UK£1.091
Jan ’22UK£0.48
UK£1.50
+214.1%
0%UK£1.50UK£1.50UK£1.191
Dec ’21UK£0.40
UK£1.50
+272.7%
0%UK£1.50UK£1.50UK£1.371
Nov ’21UK£0.45
UK£1.50
+237.1%
0%UK£1.50UK£1.50UK£1.221

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies